Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Alpha-1 Antitrypsin Drugs
... at a CAGR of 9.6% over the analysis period 2024-2030. Prolastin C Drugs, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.1 Billion by the end ... Read More
-
Ampoules Packaging
... CAGR of 6.2% over the analysis period 2024-2030. Glass Material, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$5.6 Billion by the end of the analysis ... Read More
-
Bioburden Testing
... CAGR of 11.3% over the analysis period 2024-2030. Bioburden Testing Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the ... Read More
-
Pharmacy Automation
... CAGR of 6.9% over the analysis period 2024-2030. Medication Dispensing Systems, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$3.3 Billion by the end of the ... Read More
-
Pharmaceutical Contract Packaging
... at a CAGR of 5.8% over the analysis period 2024-2030. Primary Packaging, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$25.7 Billion by the end of ... Read More
-
Carglumic Acid
... CAGR of 5.3% over the analysis period 2024-2030. Orally Disintegrating Tablets Delivery, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$105.6 Million by the end of ... Read More
-
Calcium Channel Blockers
... at a CAGR of 6.1% over the analysis period 2024-2030. Dihydropyridine Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$17.1 Billion by the end of ... Read More
-
Antibiotics
... 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in ... Read More
-
Personalized Nutrition
... CAGR of 13.5% over the analysis period 2024-2030. Active Measurement, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$27.5 Billion by the end of the analysis ... Read More
-
Pharmaceutical Cartridges
... CAGR of 6.8% over the analysis period 2024-2030. GlassMaterial, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$2.0 Billion by the end of the analysis period. ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Epilepsy Drugs
... CAGR of 3.8% over the analysis period 2024-2030. First Generation Drugs, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Nanocapsules
... 6.3% over the analysis period 2024-2030. Oncology Therapy Area, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. ... Read More
-
Bio Decontamination
... CAGR of 4.5% over the analysis period 2024-2030. Bio Decontamination Equipment, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$122.1 Million by the end of the ... Read More
-
Healthcare Contract Research Organization (CRO)
... Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Clinical CRO, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$68.2 Billion ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Middle East & Africa Halal Pharmaceuticals Market Forecast 2025-2032
... and the forecasting years are from 2025 to 2032. MARKET INSIGHTS The halal pharmaceuticals market in the Middle East & Africa has experienced significant growth due to a combination of rising consumer demand and regulatory ... Read More
-
ePedigree Software
... CAGR of 17.3% over the analysis period 2024-2030. On-Premise Deployment, one of the segments analyzed in the report, is expected to record a 16.5% CAGR and reach US$4.6 Billion by the end of the analysis ... Read More
-
Coenzyme Q10
... CAGR of 4.5% over the analysis period 2024-2030. Dietary Supplements Application, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$609.1 Million by the end of the ... Read More
-
Analgesics
... 5.3% over the analysis period 2024-2030. Prescription Analgesics, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$43.8 Billion by the end of the analysis period. Growth ... Read More
-
Contract Research Organization Services (CROs)
... Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Clinical Research Services, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$76.7 ... Read More
-
Pharmaceutical Packaging
... CAGR of 8.2% over the analysis period 2024-2030. Plastics & Polymers Material, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$114.0 Billion by the end of ... Read More
-
Human Growth Hormone Drugs
... 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the ... Read More
-
RFID in Healthcare
... at a CAGR of 14.6% over the analysis period 2024-2030. RFID Tags, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$8.5 Billion by the end of ... Read More
-
Active Pharmaceutical Ingredients (API)
... 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative APIs, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the ... Read More
Research Assistance
